FDA Office Of Nonprescription Drugs To Assume Switch Management Duties
This article was originally published in The Tan Sheet
Executive Summary
FDA's recently-christened Office of Nonprescription Drugs will take over project management responsibilities for Rx-to-OTC switches from the primary review division within the Center for Drug Evaluation & Research, according to the agency
You may also be interested in...
FDA Clearance May Thwart Monograph Goal; Ganley Talks Turkey About ONP
The Office of Nonprescription Products' goal of completing all OTC monographs by 2010 is viable only if FDA improves its document clearance process, according to ONP head Charles Ganley, MD
ONP: Leaner, Meaner In 2006
Director of the Office of Nonprescription Products Charles Ganley, MD, and Assistant Director Susan Johnson, PhD, met with industry stakeholders at a conference Feb. 1 to present an overview of the status of ONP in 2006. The department heads discussed FDA's plans to set a final deadline on monograph clearance and improve internal communication and NDA review, and made several suggestions on how industry can help FDA do its job..
Nonprescription Office In Transition Works To Hire Division Heads
Filling the posts of division directors is the current primary focus for Office of Nonprescription Products Director Charles Ganley, MD